Business
Cytokinetics Announces Vision 2025 and Outlines 2020 Corporate Milestones
Top-line Results from GALACTIC-HF Now Expected in Q4 2020; Commercial Readiness Underway REDWOOD-HCM Initiated; Second Cardiac Myosin Inhibitor Planned to
About this update from Cytokinetics, Incorporated
[{"type":"text","content":"Top-line Results from GALACTIC-HF Now Expected in Q4 2020; Commercial Readiness Underway\n REDWOOD-HCM Initiated; Second Cardiac Myosin Inhibitor Planned to Enter Clinic in 1H 2020 SOUTH SAN FRANCISCO, Calif., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today announced its Vision 2025 and provided guidance for corporate milestones expected to occur in 2020. The company’s Vision 2025: “Leading with Science, Delivering for Patients,” articulates its five-year key imperatives enabling Cytokinetics to be the leading muscle biology biopharmaceutical company that meaningfully improve the lives of patients with diseases of impaired muscle function through access to novel medicines arising from its research. Key imperatives for Vision 2025 include: Achieve regulatory approvals for at least two drugs arising from our pipelineBuild commercial capabilities to market and sell our medicines reflective of their innovation and valueGenerate sustainable and growing revenues from product salesDouble our development pipeline to include ten therapeutic programsExpand our discovery platform to muscle energetics, growth and metabolismBe the science-driven company people want to join and partner with “Our company transformation began five years ago when we outlined our Vision 2020,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “We effectively executed on those initiatives so that we are now well positioned to look forward to the next five-year horizon and the profound privilege to potentially bring forward to patients at least two new medicines from our pioneering muscle biology focused research. We expect to deliver on the promise of our science and to double our pipeline of novel mechanism drug candidates and expand the breadth of our discovery platform. As we execute against our vision, we will support disease advocacy groups elevating the patient voice and live by our values of integrity, fairness and compassion in all that we do.” In addition, the company announced its expected 2020 milestones. “To ensure that we deliver on the promise of our science for patients, we recognize that we must continue to plan and execute well in connection with expected milestones in 2020,” continued Mr. Blum. “This will be a pivotal year for Cytokinetics as we now expect trial results from GALACTIC-HF by the end...